ARTICLE | Company News

Ark, Calibr in COPD deal

November 10, 2017 9:27 PM UTC

Ark Biosciences Inc. (Shanghai, China) partnered with the California Institute for Biomedical Research (La Jolla, Calif.) to develop “first-in-class” therapies for chronic obstructive pulmonary disease and related lung diseases. Ark said it will be responsible for preclinical and clinical development.

Ark's lead candidate, AK0529, is in Phase II testing to treat respiratory syncytial virus (RSV) infection. Ark has exclusive, worldwide rights to develop and commercialize the small molecule inhibitor of RSV F protein from Roche (SIX:ROG; OTCQX:RHHBY) under a 2014 deal...